Development of Immunotherapy for Pancreatic Cancer

Yutaka Kawakami, Takaho Okada, Masanori Akada

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Human tumor antigens recognized by T cells have been recently identified in various cancers, including pancreatic cancer. With the identified antigens, new immunotherapies can be developed using more efficient immunologic intervention (due to sufficient amounts of antigens in a more immunogenic form), as well as more quantitative and qualitative immunomonitoring. Various immunotherapies for patients with various cancers, including pancreatic cancer, are currently under evaluation in clinical trials. These include adoptive transfer of tumor reactive T cells and LAK cells; nonmyeloablative stem cell transplantation; active immunization with the identified tumor antigens, various tumor-derived products, dendritic cells pulsed with tumor antigens, and gene-modified tumor cells. Although these efforts in the realm of pancreatic cancer are still limited, various groups in Japan continue to be actively involved in this field of research.

Original languageEnglish
Pages (from-to)320-325
Number of pages6
JournalPancreas
Volume28
Issue number3
DOIs
Publication statusPublished - 2004 Apr

Fingerprint

Pancreatic Neoplasms
Immunotherapy
Neoplasm Antigens
Neoplasms
T-Lymphocytes
Antigens
Lymphokine-Activated Killer Cells
Adoptive Transfer
Stem Cell Transplantation
Dendritic Cells
Japan
Vaccination
Clinical Trials
Research
Genes

Keywords

  • Dendritic cells
  • Graft versus tumor effects
  • Immunotherapy
  • T cells
  • Tumor antigens

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

Development of Immunotherapy for Pancreatic Cancer. / Kawakami, Yutaka; Okada, Takaho; Akada, Masanori.

In: Pancreas, Vol. 28, No. 3, 04.2004, p. 320-325.

Research output: Contribution to journalArticle

Kawakami, Y, Okada, T & Akada, M 2004, 'Development of Immunotherapy for Pancreatic Cancer', Pancreas, vol. 28, no. 3, pp. 320-325. https://doi.org/10.1097/00006676-200404000-00021
Kawakami, Yutaka ; Okada, Takaho ; Akada, Masanori. / Development of Immunotherapy for Pancreatic Cancer. In: Pancreas. 2004 ; Vol. 28, No. 3. pp. 320-325.
@article{7b509320d9c84d32b7ec95e945cf3bf4,
title = "Development of Immunotherapy for Pancreatic Cancer",
abstract = "Human tumor antigens recognized by T cells have been recently identified in various cancers, including pancreatic cancer. With the identified antigens, new immunotherapies can be developed using more efficient immunologic intervention (due to sufficient amounts of antigens in a more immunogenic form), as well as more quantitative and qualitative immunomonitoring. Various immunotherapies for patients with various cancers, including pancreatic cancer, are currently under evaluation in clinical trials. These include adoptive transfer of tumor reactive T cells and LAK cells; nonmyeloablative stem cell transplantation; active immunization with the identified tumor antigens, various tumor-derived products, dendritic cells pulsed with tumor antigens, and gene-modified tumor cells. Although these efforts in the realm of pancreatic cancer are still limited, various groups in Japan continue to be actively involved in this field of research.",
keywords = "Dendritic cells, Graft versus tumor effects, Immunotherapy, T cells, Tumor antigens",
author = "Yutaka Kawakami and Takaho Okada and Masanori Akada",
year = "2004",
month = "4",
doi = "10.1097/00006676-200404000-00021",
language = "English",
volume = "28",
pages = "320--325",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Development of Immunotherapy for Pancreatic Cancer

AU - Kawakami, Yutaka

AU - Okada, Takaho

AU - Akada, Masanori

PY - 2004/4

Y1 - 2004/4

N2 - Human tumor antigens recognized by T cells have been recently identified in various cancers, including pancreatic cancer. With the identified antigens, new immunotherapies can be developed using more efficient immunologic intervention (due to sufficient amounts of antigens in a more immunogenic form), as well as more quantitative and qualitative immunomonitoring. Various immunotherapies for patients with various cancers, including pancreatic cancer, are currently under evaluation in clinical trials. These include adoptive transfer of tumor reactive T cells and LAK cells; nonmyeloablative stem cell transplantation; active immunization with the identified tumor antigens, various tumor-derived products, dendritic cells pulsed with tumor antigens, and gene-modified tumor cells. Although these efforts in the realm of pancreatic cancer are still limited, various groups in Japan continue to be actively involved in this field of research.

AB - Human tumor antigens recognized by T cells have been recently identified in various cancers, including pancreatic cancer. With the identified antigens, new immunotherapies can be developed using more efficient immunologic intervention (due to sufficient amounts of antigens in a more immunogenic form), as well as more quantitative and qualitative immunomonitoring. Various immunotherapies for patients with various cancers, including pancreatic cancer, are currently under evaluation in clinical trials. These include adoptive transfer of tumor reactive T cells and LAK cells; nonmyeloablative stem cell transplantation; active immunization with the identified tumor antigens, various tumor-derived products, dendritic cells pulsed with tumor antigens, and gene-modified tumor cells. Although these efforts in the realm of pancreatic cancer are still limited, various groups in Japan continue to be actively involved in this field of research.

KW - Dendritic cells

KW - Graft versus tumor effects

KW - Immunotherapy

KW - T cells

KW - Tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=1842430506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842430506&partnerID=8YFLogxK

U2 - 10.1097/00006676-200404000-00021

DO - 10.1097/00006676-200404000-00021

M3 - Article

C2 - 15084980

AN - SCOPUS:1842430506

VL - 28

SP - 320

EP - 325

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -